Minerva Advisors LLC Lumos Pharma, Inc. Transaction History

Minerva Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jan 31, 2024	SELL	$3.01 - $4.38 $22,472 - $32,701	-7,466 Reduced 21.95%	26,549 $87,000
Q2 2023 Aug 10, 2023	SELL	$3.01 - $4.38 $22,472 - $32,701	-7,466 Reduced 21.95%	26,549 $84,000
Q1 2023 Jan 31, 2024	BUY	$3.16 - $4.0 $107,487 - $136,060	34,015 New	34,015 $112,000
Q4 2022 Jan 31, 2024	BUY	$3.05 - $9.52 $103,745 - $323,822	34,015 New	34,015 $122,000
Q3 2021 Nov 12, 2021	BUY	$7.36 - $11.36 $250,350 - $386,410	34,015 New	34,015 $321,000

2.2M

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

Get notified when there are updates to the investment portfolio of Minerva Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Minerva Advisors LLC with notifications on news.